Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Bubble signal: +1 · Overheating evidenceRelevance 74FundingUS
Source: TechCrunch AI · Published 2026-09-23
Summary
AI biotech company Enveda has raised $311 million, valuing the company at $2 billion. It is currently testing drugs for skin conditions and for preserving weight loss after patients stop taking GLP-1 drugs.
Bubble analysis
This is a concrete AI-linked funding round, adding to the money-inflow side of the bubble question and showing that AI branding still attracts large venture checks. But it is a single biotech company's round, far removed from the AI infrastructure capex-versus-revenue debate, so it speaks only indirectly to whether AI is in an investment bubble.
#valuation#funding#startup#biotech
Read original ↗Related signals
linked by shared tags
- Photon held a funeral for mobile apps. Now it has $4.5M to help replace them with agents.#funding#startup
- Valor, Atreides, and Sequoia back AI startup Flow Engineering at $750M valuation#valuation#funding
- Racing to List Before Thanksgiving: Anthropic Said to Seek IPO as Early as Mid-November#valuation
- Nvidia-Backed Firmus Plans Australian IPO at $30 Billion Target Valuation#funding
- Bank of England Governor: "Must Prepare for Market Shock If AI Bubble Bursts"#valuation